Vertex Pharma (VRTX) Granted European CHMP Positive Opinion for KALYDECO for Children/Adolescents with CF and R117H Mutation in CFTR Gene
Go back to Vertex Pharma (VRTX) Granted European CHMP Positive Opinion for KALYDECO for Children/Adolescents with CF and R117H Mutation in CFTR Gene| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 510.72 +2.38 (0.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $508.34 | 52 Week High | $134.71 | |||
| Open | $506.85 | 52 Week Low | $73.31 | |||
| Day High | $514.10 | P/E | N/A | |||
| Day Low | $501.01 | EPS | $-1.98 | |||
| Volume | 906,636 | |||||
